Dashboard/BMY/CAMZYOS/event

Enroll.Enrollment Complete

ODYSSEY-HCM Phase 3 Enrollment Complete (nHCM)

BMY·CAMZYOS·Hypertrophic Cardiomyopathy·

Approved

·NCT04349072

current best date

JUN

2026

MONTH2 months

Takeaway

Procedural milestone: enrollment finishes for the Phase 3 trial of CAMZYOS in non-obstructive HCM. Anchors the Q2 2027 readout date.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~100%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAcardiac myosin inhibitor

CAMZYOS (mavacamten) is a first-in-class oral cardiac myosin inhibitor developed by Bristol Myers Squibb that treats hypertrophic cardiomyopathy (HCM) — a genetic condition in which the heart muscle thickens abnormally and obstructs blood flow. The drug reduces the number of myosin-actin cross-bridges that form during each heartbeat, decreasing the force of contraction and relieving the outflow obstruction that causes breathlessness, chest pain, and syncope. CAMZYOS is approved for symptomatic obstructive HCM and is being studied in non-obstructive HCM — a distinct phenotype with twice the patient population and no approved drug therapy — in an ongoing Phase 3 trial.

Indication

Cardiology - HFpEF

Hypertrophic Cardiomyopathy

MeSH · D002311

No primer in glossary yet.

Trial

active

NCT04349072 ↗

ODYSSEY-HCM Phase 3 Mavacamten in nHCM

Prior BMY reactions to Enroll. events

1 historical event · base rate, not prediction

Median 1W move

+5.3%

Median 1M move

+3.9%

Positive outcomes

1/ 1

100%

Negative outcomes

0/ 1

Date	Headline	Outcome	1W	1M	6M
Jan 2026	CAMZYOS — Pivotal Enrollment Complete	positive	+5.3%	+3.9%	+6.1%

Historical BMY stock reaction to past Enroll. catalysts. Past performance is not a forecast — base rates anchor expectations, not outcomes. Positive rate 100%.

Disclosure trail

1 observation · sorted by confidence

Apr 22, 2026·8d agopinned · highest confidence
HIGH confPR
top claim
JUN2026
MONTH
“ODYSSEY-HCM, the Phase 3 study of CAMZYOS in non-obstructive HCM, is expected to complete enrollment in June 2026.”
conf 88%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.